New Products

New OC: FDA says 'yes' to Yaz

The idea is to reduce monthly hormonal fluctuations compared to traditional OCs, which have regimens of 21 days of active pills and 7 days of placebo. Yaz hit the U.S. market in April. (Berlex had already been marketing Yasmin, a 21-day formulation pill.)

Upper respiratory infections, headache, yeast infection, and breast pain are among the drug's most common adverse effects. Patients who would like more information about Yaz can call 1-888-BERLEX-4 or visit the product Web site at http:// http://www.yaz.com/.

'How-to' manual covers obstetric intensive care

Wider availability of Fetal Fibronectin Test

Adeza has announced that Quest Diagnostics Incorporated will now be offering reference laboratory service to physicians nationwide for Adeza's FullTerm, The Fetal Fibronectin Test. With this agreement, Quest Diagnostics will be analyzing fetal fibronectin test samples collected from patients by physicians' offices and clinics nationwide through its national network of labs and patient service centers. Previously, it was doing so only on a limited basis.

The Fetal Fibronectin Test, approved by the FDA to help in assessing risk of preterm birth, uses a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. For more information, visit the company Web site at http:// http://www.adeza.com/.